Grifols, S.A. (GRFS) News

Grifols, S.A. (GRFS)

Today's Latest Price: $16.86 USD

0.47 (-2.71%)

Updated Oct 29 4:00pm

Add GRFS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter GRFS News Items

GRFS News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest GRFS News From Around the Web

Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Plasma Fractionation Market to Grow at Rapid Pace by 2025 With Major Key Players : Grifols, CSL, Kedrion, BPL

The Plasma Fractionation market 2020 report includes thorough gathering of the quantitative analysis of the industry in order to assist players to grow in the market. Perceptions on specific revenue figures generated are also given in the report. This

OpenPR | October 2, 2020

Worldwide Plasma Fractionation Industry to 2025 - Featuring CSL, Grifols & Shire Among Others

DUBLIN, Oct. 1, 2020 /PRNewswire/ -- The "Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) - Global Forecast…

PR Newswire | October 1, 2020

Intravenous Immunoglobulin (IVIg) Market Foreseen to Draw a Promising Growth of $10.8 Billion by 2025 | Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, CNBG

Global Intravenous Immunoglobulin (IVIg) Market Synopsis: The Intravenous Immunoglobulin (IVIg) Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Intravenous Immunoglobulin (IVIg) market size to maintain the average annual growth rate of

OpenPR | September 29, 2020

Worldwide Therapeutic Drug Monitoring Industry to 2025 - Players Include Biomerieux, Theradiag & Grifols Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The global therapeutic drug monitoring market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025. The growth of t

Business Wire | September 23, 2020

Worldwide Blood Collection Industry to 2025 - Featuring Terumo BCT, Fresenius Kabi & Grifols Among Others

DUBLIN , Sept. 21, 2020 /PRNewswire/ -- The "Blood Collection Market by Product (Tubes (Plasma (EDTA, Heparin, Glucose), Serum), Blood Bags, Monitors, Needles), Method (Manual, Automated), Application (Diagnostic, Therapeutic), End User (Hospitals & ASCs, Blood Banks, Labs) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The global blood collection devices market is projected to reach USD 6.47 billion by 2025 from USD 4.83 billion in 2020, at a CAGR of 6.0% between 2020 and 2025. The growth of this market is majorly driven by factors such as the increasing incidence of infectious diseases, the rising number of accidents & trauma cases, the emergence of liquid biopsy tests, and a demand for blood donations and blood components. However, complexities...

Benzinga | September 21, 2020

Grifols to acquire remaining stake in Alkahest for $146M

Grifols (GRFS) has entered into an agreement to acquire the remaining equity of Alkahest in exchange for a total price of $146M, on a debt-free basis. No additional financing will be required.The transaction is expected to close in early 2021.Alkahest is a clinical stage biopharmaceutical company dedicated to discovering and developing treatments...

Seeking Alpha | September 8, 2020

Plasma-Centric Drugmaker Grifols To Buy Geriatric Pharma Startup Alkahest

Blood plasma and diagnostics company Grifols SA (NASDAQ: GRFS ) is set to completely acquire Alkahest Inc, a biopharmaceutical startup focussed on neurodegenerative and age-related diseases, for $146 million on a debt-free basis. What Happened: Grifols will buy the remaining equity in Alkahest without having to resort to additional borrowing, the company said in a statement. The drugmaker added it's likely to complete the transaction early next year. “Now we see a wealth of plasma-derived and non-plasma therapeutic candidates … Full story available on Benzinga.com

Benzinga | September 8, 2020

Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has acquired 10% of Bloodbuy (BloodSolutions, LLC), a cloud-based marketplace that facilitates buying and selling of blood components in the U.S.

Yahoo | July 23, 2020

Grifols to acquire plasma facilities in Montreal and U.S. for $460M

Grifols (GRFS) has executed purchase arrangements with the South Korean-based GC Pharma whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of $460M. No additional financing will be required for the acquisition. Once the facilities...

Seeking Alpha | July 20, 2020

Grifols Buys Plasma Assets From Green Cross For $460M To Boost Canada Business

Grifols SA (GRFS) announced on Monday that it has acquired plasma assets in North America and a plasma facility in Montreal from South Korea’s Green Cross Pharma for a total of $460 million.Shares rose 2.4% to $20.13 in Monday’s pre-market trading. As part of the deal, the Spanish pharmaceutical company purchased 11 plasma collection centers and two purification plants in the U.S., as well as a Montreal-based plasma fractionation facility. The investment is part of Grifols’ plan to become the only large-scale commercial manufacturer of plasma products in Canada, with a capacity of 1.5 million liters a year to secure plasma-protein-product supply.The company added that Canada is a market with one of the highest rates of plasma consumption per capita in the world and one with significant ...

Yahoo | July 20, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6996 seconds.